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Abstract
Background: Neuroblastoma is a childhood cancer derived from immature cells of the sympathetic nervous
system. The disease is clinically heterogeneous, ranging from neuronal differentiated benign ganglioneuromas to
aggressive metastatic tumours with poor prognosis. Amplification of the MYCN oncogene is a well established
poor prognostic factor found in up to 40% of high risk neuroblastomas.
Using neuroblastoma cell lines to study neuronal differentiation in vitro is now well established. Several protocols,
including exposure to various agents and growth factors, will differentiate neuroblastoma cell lines into neuron-like
cells. These cells are characterized by a neuronal morphology with long extensively branched neurites and
expression of several neurospecific markers.
Results: In this study we use retrovirally delivered inducible short-hairpin RNA (shRNA) modules to knock down
MYCN expression in MYCN-amplified (MNA) neuroblastoma cell lines. By addition of the inducer doxycycline, we
show that the Kelly and SK-N-BE(2) neuroblastoma cell lines efficiently differentiate into neuron-like cells with an
extensive network of neurites. These cells are further characterized by increased expression of the neuronal
differentiation markers NFL and GAP43. In addition, we show that induced expression of retrovirally delivered anti-
MYCN shRNA inhibits cell proliferation by increasing the fraction of MNA neuroblastoma cells in the G1 phase of
the cell cycle and that the clonogenic growth potential of these cells was also dramatically reduced.
Conclusion: We have developed an efficient MYCN-knockdown in vitro model system to study neuronal
differentiation in MNA neuroblastomas.
Background
Neuroblastoma is a childhood cancer arising from the
sympaticoadrenal lineage of the neural crest. It is char-
acterized by diverse clinical behaviours ranging from
spontaneous regression, maturation to more benign
forms (ganglioneuroblastoma or ganglioneuroma), to
rapid tumour progression and death [1]. Amplification
of the MYCN oncogene has been considered the most
important prognostic factor for progressive disease and
poor outcome. Despite intense efforts to elucidate a
mechanism by which MYCN overexpression acts to pro-
mote the aggressive phenotype, the functional roles of
the MYCN protein in neuroblastoma are poorly under-
stood [2].
Several alternative mechanisms for neuroblastoma
regression have been proposed over the past 20 years,
although the principal mechanism underlying this pecu-
liar phenomenon remains to be fully elucidated [3-5].
Tumour maturation via neuronal differentiation has
recently been proposed as a plausible candidate mechan-
ism to explain neuroblastoma regression [6]. Therefore,
the study of neuroblastoma as a model system for the
general process of tumour cell differentiation, as well as
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of both tumour maturation and spontaneous regression.
Using neuroblastoma cell lines to study neuronal dif-
ferentiation in vitro is now well established. Induced
neuron-like morphological and biochemical changes to
the SH-SY-5Y neuroblastoma cell line was demon-
strated almost 30 years ago using a bioactive phorboles-
ter as the inducing agent [7]. Since then, a variety of
various agents and growth factors have been shown to
induce neuronal differentiation in many neuroblastoma
cell lines (reviewed in [8]). Furthermore, specific sup-
pression of MYCN expression using traditional antisense
techniques or small interfering RNA molecules (siRNA)
have also been shown to promote neuronal differentia-
tion in several MYCN-amplified (MNA) neuroblastoma
cell lines [9-12].
Plasmid and viral vector-based systems containing
RNA polymerase III promoters for the expression of
short hairpin RNAs (shRNAs) have become useful tools
for modulating gene expression in mammalian cells
[13]. Compared to siRNAs, the use of shRNAs to sup-
press gene function has been demonstrated to be more
effective [14]. In addition, shRNA-based strategies offer
the advantage of inducible expression in situations in
which gene knockdown is expected to have a deleterious
effect on the targeted cell.
Retroviral expression systems have proven to be useful
tools for sustained long-term expression of transgenes
in mammalian cells [15]. With the development of
protocols to produce high-titer infectious, replication-
incompetent retroviral particles, these expression sys-
tems are now commonly used for shRNA delivery.
In this study, we have developed a retroviral tetracy-
cline-inducible anti-MYCN shRNA expression system to
study MYCN knockdown-mediated neuronal differentia-
tion in MNA neuroblastoma cell lines. We reveal that
MNA neuroblastoma cell lines induced to express the
anti-MYCN shRNAs efficiently undergo morphological
and biochemical changes consistent with neuronal
differentiation.
Results and Discussion
Retrovirally delivered inducible shRNA expression in
HEK293T-Rex cells
We have previously developed and characterized an effi-
cient doxycyclin (dox)-inducible variant of the H1 pro-
moter (H1-2O2-US/DS) for shRNA expression in
human cells. The H1-2O2-US/DS promoter was shown
to be almost completely inactive in the non-induced
state, while induction by dox yielded a high shRNA
expression in transient transfection studies using an
anti-luciferase (anti-luc) shRNA reporter system [16].
As a first step towards developing a long-term induci-
ble shRNA expression system, we subcloned the
previously described anti-luc shRNA constructs and the
corresponding scrambled control shRNA into a retroviral
expression vector. shRNA-expressing retroviruses were
transduced into HEK293T-Rex cells followed by transient
transfection of the luciferase reporter vector. Two days
after transfection, cells were monitored for dox-regulated
shRNA expression. Addition of dox to the transduced
cells had only minor effects on luciferase expression as
can be seen from both the inducible scrambled negative
control (H1-2O2 Scr) and the H1-wt expressed anti-luc
shRNA (H1-wt a-Luc) (Figure 1). Induction of anti-luc
shRNA expression from the H1-2O2 promoter by the
addition of dox downregulated the luciferase reporter to
levels similar to that observed for the H1-wt promoter.
At the same time, no transcriptional activity was
observed in the non-induced state (H1-2O2 aLuc, -dox)
when compared to the scrambled shRNA control.
These data clearly show that retroviral delivery of the
H1-2O2 US/DS-inducible shRNA expression system to
HEK293T-Rex cells allows an efficient inducible expres-
sion of mature shRNA molecules.
Efficient downregulation of MYCN expression in MNA
neuroblastoma cell lines
We have previously designed an anti-MYCN shRNA
construct (aMN-887) for downregulation of MYCN
oncogene expression in MYCN-amplified (MNA) neuro-
blastoma cells [17]. This design procedure was based on
the original Hannon protocol for shRNA construction,
recommending 29 bp stem structures [18]. We have
Figure 1 Retrovirally delivered inducible shRNA expression in
HEK293 cells. TetR-expressing HEK293 cells (HEK293T-Rex) were
transduced with retroviruses expressing anti-Luciferase (a-Luc) or
scrambled (Scr) shRNAs. The a-Luc shRNA was expressed from a wt-
H1 or the inducible H1-2O2 promoter in the absence (-) or presence
(+) of 1 μg/ml doxycyclin (dox) for 48 hrs. Error bars indicate SDs.
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(aMN-1658) targeting the 3’UTR of the MYCN mRNA.
The MNA Kelly and SK-N-BE(2) neuroblastoma cell
lines were transiently transfected with plasmids expres-
sing the aMN-887 or aMN-1658 shRNAs. A scrambled
shRNA (Scr) construct was used as the control. Three
days after transfection, cells receiving the aMN (anti-
MYCN) shRNAs appeared to have a more neuron-like
phenotype characterized by neurite outgrowth, while
cells transfected with the control shRNA did not reveal
any morphological alterations as compared to non-
transfected cells (Figure 2). Western immunoblot and
quantitative real-time RT-PCR analysis confirmed speci-
f i cs u p p r e s s i o no ft h eM Y C Np r o t e i na n dMYCN
mRNA in both cell lines, respectively (Figure 3a and
Figure 3b).
Consistent with previous data, an inverse correlation
between MYCN and c-MYC mRNA expression was also
confirmed (Figure 3c) [19,20]. The observed morpholo-
gical changes were documented biochemically by
increased expression of the early neuronal differentiation
marker NFL (Figure 3d). Furthermore, expression of
aMN-1658, but not of aMN-887, resulted in a marked
increase in the late neuronal differentiation marker
GAP43, which is known to be involved in axonal out-
growth and synapse formation (Figure 3e) [21]. This
observation is consistent with the more extensive neuro-
nal differentiation observed for both Kelly and SK-N-BE
(2) cells transfected with aMN-1658 compared to cells
transfected with aMN-887 (Figure 2).
These data show that aMN-1658 is an efficient anti-
MYCN shRNA construct which suppresses MYCN
expression and induces prominent neuronal differentia-
tion in MNA neuroblastoma cell lines. For that reason,
the aMN-1658 shRNA was used in the following
research to knock down MYCN expression.
Previous reports document conflicting results on cell
cycle distribution data of SK-N-BE(2) cells treated with
anti-MYCN siRNAs. While Yu et al. reported no appar-
ent difference in the fraction of G1 cells after siRNA
treatment, Bell et al. showed that MYCN siRNA treat-
ment increased the G1 population by 8.1% compared to
Figure 2 MYCN knockdown induces neurite outgrowth in MNA neuroblastoma cell lines. MNA Kelly (A) and SK-N-BE(2) (B) cells transiently
transfected for 3 days with anti-MYCN (aMN-887 and aMN-1658) and scrambled (Scr control) shRNA expressing plasmids. Cells expressing the
aMN shRNAs show neurite outgrowth characteristic of neuronal differentiated cells. White arrows indicate neurite outgrowth.
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investigate the effect of shRNA-mediated MYCN knock-
down on the cell cycle distribution pattern, we transi-
ently transfected SK-N-BE(2) cells with plasmids
expressing the aMN-887, aMN-1658 or a scrambled
shRNA from a wt H1 promoter. Three days posttrans-
fection the cell cycle distribution pattern was monitored
using flow cytometry. The fraction of cells in the G1
phase of the cell cycle increased from 57% (Scr) to 74%
for SK-N-BE(2) cells transfected with the aMN-1658
shRNA (Figure 3f). Similar results were obtained with
aMN1658-transfected Kelly cells (Figure 3g).
A discrepancy between the knockdown levels for the
MYCN protein (85-94%) and mRNA (45-70%) was
observed in our MYCN shRNA knockdown experiments,
with similar results being previously reported for MYCN
siRNA knockdown by others [23]. In order to further
document that only the expression of the MYCN shRNAs
results in reduced MYCN expression, we set up additional
experiments. The complete MYCN 3’UTR sequence,
including the aMN-1658 target sequence, was cloned
behind a luciferase reporter gene in the pMIR-REPORT
vector (Ambion). Co-transfecting this reporter vector and
the aMN-shRNA expressing plasmids into HEK-293 cells
demonstrated the specific knockdown, monitored as an
80% reduction in luciferase activity, by the aMN-1658
shRNA (Additional file 1a). When aMN-1658 was co-
transfected with a control reporter vector containing a
3’UTR lacking the aMN-1658 target sequence (Luc NT-
3’UTR), no change in luciferase expression was observed,
and similar results were obtained in the non-MNA neuro-
blastoma cell line SH-SY-5Y (data not shown).
In addition, we co-expressed the aMN-shRNA con-
structs and the MYCN cDNA lacking the 3’UTR
sequence in a MNA neuroblastoma cell line. Downregu-
lation of both the endo- and exogenously expressed
MYCN protein was only observed for the aMN-887
shRNA targeting the coding region of MYCN.T h e
aMN-1658 shRNA was not able to suppress the exogen-
ously expressed MYCN cDNA lacking the 3’UTR struc-
ture (Additional file 1b).
These experiments show that the aMN-1658 shRNA
specifically reduces expression of mRNAs containing the
MYCN 3’UTR target. However, we have not been able
to confirm or rule out the possibility that a part of the
MYCN protein reduction by aMN-1658 shRNA knock-
down is mediated by a miRNA-like mechanism not
involving mRNA degradation. Nonspecific cellular
effects induced by shRNA expression were excluded by
showing that the expression level of several genes
involved in the interferon response (OAS2, MX1,
IFITM1 and ISGF3g) remained unaltered during trans-
fection of various shRNA constructs (data not shown).
Retrovirally delivered inducible anti-MYCN shRNA
expression in MNA neuroblastoma cell lines
In order to generate a long-term inducible anti-MYCN
shRNA expression system, we first cloned the aMN-
1658 shRNA module behind the inducible H1-2O2-US/
DS promoter and then gated the resulting construct
into a retroviral expression vector to generate pRV-
1658. A similar vector expressing a scrambled shRNA
was constructed as a negative control (pRV-Scr).
Kelly and SK-N-BE(2) neuroblastoma cell lines stably
expressing the TetR (tetracycline repressor) were trans-
duced with the retroviruses RV-1658 and RV-Scr and
then incubated for 6 days in a growth medium both
with and without dox. As can be seen from Figure 4a
Figure 3 Transient MYCN knockdown in MNA Kelly and SK-N-
BE(2) cells using shRNA technology.( A): A representative western
blot analysis of MYCN protein expression in Kelly and SK-N-BE(2)
cells transiently transfected for 3 days with plasmids expressing the
aMN-887 and aMN1658 shRNAs. b-actin expression was used for
normalization. Quantitative real-time RT-PCR was used to investigate
the expression of MYCN (B), c-MYC (C), neurofilament light-chain -
NFL (D) and growth-associated protein 43 - GAP43 (E) mRNAs. Error
bars indicate SDs. (F) and (G): Flow cytometric analyses showing the
cell cycle distribution of SK-N-BE(2) and Kelly cells transiently
transfected with the aMN-887 and aMN-1658 shRNA expressing
plasmids. Scr indicates the scrambled shRNA controls.
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morphology of Kelly (A) and SK-N-BE(2) (B) cells transduced with retroviruses delivering the dox-inducible aMN-1658 shRNA module (RV-1658).
RV-Scr indicates the cells receiving retroviruses delivering an inducible scrambled shRNA module. (C): A representative western blot showing
MYCN and NFL expression in Kelly and SK-N-BE(2) cells transduced with retrovirus RV-1658 and induced to express the shRNA by addition of
1 μg/ml doxycyclin (dox).
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aMN-1658 shRNA demonstrated prominent neuronal
differentiation. The lack of morphological changes in
non-induced RV-1658 transduced cells indicates that
the H1-2O2 promoter shows minimal transcriptional
leakage in the absence of dox. The addition of dox to
RV-Scr transduced cells had no significant effect on the
cell morphology. Western blot analysis of the retrovi-
rally transduced Kelly and SK-N-BE(2) cells revealed
efficient repression of MYCN expression in cells
induced to express the aMN-1658 shRNA (Figure 4c).
Similar to the observations made in transient expression
analyses, the MYCN mRNA levels were reduced to a les-
ser extent when compared to the western blot data (data
not shown and Figure 5b).
In order to investigate the reversibility of the inducible
retroviral shRNA expression system, we performed a
time-course experiment in which the aMN-1658 expres-
sion was turned on for 3 days before removing dox
from the media for another 3 days to eliminate shRNA
expression.
Compared to the differentiated cells continuously
exposed to aMN-1658 shRNA for 6 days, no significant
change in cell morphology was observed when shRNA
expression was turned off (data not shown). When the
MYCN protein and mRNA levels were measured during
the 6 days of shRNA induction, a steady decrease in
MYCN expression was observed. Removal of dox from
the media after 3 days of exposure did not efficiently
recover MYCN expression. Consistent with the observed
neuron-like phenotype, GAP43 protein levels remained
high after dox removal (Figure 5a and Figure 5b).
By the use of a quantitative RT-PCR protocol designed
to measure the mature antisense shRNA strand, we
observed a maximum 90-fold increase in aMN-1658
RNA after 3 days of dox induction in the Kelly cells
(Figure 5c). After additional 3 days of induction, a slight
decrease in shRNA expression was observed. For the
SK-N-BE(2) cell line, a maximum 50-fold increase in
shRNA expression was observed after 6 days of continu-
ous induction. Removing the inducing agent from the
media did not efficiently cease shRNA expression. We
suggest that this lack of reversibility is most likely due
to high intracellular shRNA stability and/or insufficient
removal of dox from the media.
We also analysed the expression of the neuronal dif-
ferentiation markers NFL and GAP43 in Kelly and SK-
N-BE(2) cells transduced with shRNA-expressing retro-
viruses. Consistent with the observed morphological
changes towards a neuronal phenotype, both differentia-
tion markers increased upon aMN-1658 induction
(Figure 5a, Additional file 2a and Additional file 2b).
Quantitative real-time PCR revealed a 5-8 fold increase
in NFL mRNA and a 3-fold increase in GAP43 mRNA
in both cell lines induced to express the aMN-1658
shRNA.
SK-N-BE(2) has previously been described as a nora-
drenergic neuroblastoma cell line based on expression
of enzymes involved in neurotransmitter synthesis [24].
In order to get further information about the neuronal
phenotype observed in our experiments, we investigated
the expression levels of the cholinergic markers choline
acetyl transferase (ChAT) and vesicular acetylcholine
transporter (VAChT), and the catecholaminergic marker
tyrosine hydroxylase (TH). When Kelly and SK-N-BE(2)
cells were induced to differentiate by MYCN knockdown
we observed increased mRNA expression levels of ChAT
and VAChT. The mRNA levels of TH decreased during
the same treatment (Additional file 2c). These data are
Figure 5 Induced anti-MYCN shRNA expression decreases
MYCN and increases GAP43 expression in MNA neuroblastoma
cells. (A) A representative western blot analysis of MYCN, GAP43
and b-actin protein expression in Kelly and SK-N-BE(2) cells induced
to express the aMN-1658 shRNA. Real-time RT-PCR analysis of MYCN
mRNA (B) and aMN-1658 shRNA (C) expression was performed on
total RNA isolated from Kelly and SK-N-BE(2) cells treated as
described. Cells were transduced with retrovirus RV-1658 and
incubated for the indicated numbers of days in the presence (+) or
absence (-) of 1 μg/ml doxycyclin (dox). 3/3 and +/- indicate that
the cells were incubated for 3 days in the presence of dox, followed
by 3 days in the absence of dox. Error bars indicate SDs.
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cholinergic neuronal phenotype. A similar switch in
neuronal phenotype, including increased NPY expres-
sion, has previously been reported for a neuroblastoma
cell line induced to differentiate by a combination of
retinoic acid (RA) and brain-derived neurotropic factor
(BDNF) [25]. Differentiated neuroblastoma tumours
have recently been shown to have cholinergic character-
istics as compared to poorly-differentiated or undifferen-
tiated neuroblastomas [26].
In summary, our data show that retroviral delivery of
inducible anti-MYCN shRNAs to MNA neuroblastoma
cells efficiently reduces MYCN protein expression and
induces neuronal differentiation.
Induced anti-MYCN shRNA expression inhibits cell
proliferation and clonogenic growth of MNA
neuroblastoma cells
The Alamar Blue Assay was used to measure cell prolif-
eration in MNA neuroblastoma cells induced to express
the anti-MYCN shRNA from retroviral vectors. Figure 6
shows that the rate of cell proliferation was selectively
decreased from day 2 in SK-N-BE(2) and day 3 in Kelly
cells induced to express the aMN-1658 shRNA. Cells
expressing the scrambled shRNA showed no differences
in cell proliferation due to the presence or absence of
dox. The slight reduction in cell proliferation observed
in the non-induced aMN-1658 transduced cells is most
likely due to a small leakage from the shRNA-expressing
promoter. The delayed decrease in cell proliferation
observed in Kelly cells is consistent with the ~5-fold
higher MYCN mRNA levels in comparison to MNA SK-
N-BE(2) [27,28].
The observed reduction in the proliferation of cells
induced to express the anti-MYCN shRNA was further
investigated by flow cytometry in order to elucidate the
cell cycle distribution pattern. Induced MYCN knock-
down in the MNA Kelly cells increased the fraction of
G1 cells from 63% to 72%. For the MNA SK-N-BE(2)
cells the fraction of G1 cells increased from 46% to 57%
u p o ni n d u c t i o no fa M N - 1 6 5 8e x p r e s s i o n .A d d i t o no f
dox alone had no effect on the cell cycle distribution
pattern in cells transduced with retroviruses expressing
a scrambled shRNA control (Additional file 3).
Finally, in vitro clonogenic assays were used to mea-
sure the reproductive cell survival in MNA neuroblas-
toma cells induced to differentiate by MYCN
knockdown. Figure 7 shows that MYCN knockdown
leads to dramatic growth inhibition only in MNA neuro-
blastoma cells induced to express the anti-MYCN
shRNA.
Together, these data indicate that the induced expres-
sion of retrovirally delivered anti-MYCN shRNA inhibits
cell proliferation by increasing the fraction of MNA
neuroblastoma cells in the G1 phase of the cell cycle.
The clonogenic growth potential of these cells was also
dramatically reduced.
Conclusion
We have developed an efficient MYCN-knockdown in
vitro model system to study neuronal differentiation in
MNA neuroblastomas.
Methods
Cell cultures and transfection
The human MYCN-amplified neuroblastoma cell lines
Kelly and SK-N-BE(2), and their derivatives SKNBE(2)-
TetR and Kelly-TetR (constitutively expressing the Tet-
racycline Repressor), were cultivated as previously
described [16]. HEK293 and Hek293 Phoenix-ampho-
pack (a kind gift from Dr. James Lorens) cells were
grown in a Dulbecco’s modified Eagle’sm e d i u m
(DMEM) [29]. HEK293-TREx cells (Invitrogen, Carls-
bad, CA, USA) were grown in DMEM with 15 μg/ml
blasticidin. All media were supplemented with 10% FBS.
Cells were maintained in a humidified 37°C incubator
Figure 6 The proliferative inhibition effect of induced MYCN
knockdown in MNA neuroblastoma cells. The Alamar Blue Assay
was used to measure cell viability in Kelly (A) and SK-N-BE(2) (B)
cells transduced with retrovirus RV-Scr (scrambled control) and RV-
1658 (anti-MYCN). The addition of doxycyclin (+ dox) induces
expression of the shRNAs. AB reduction = Alamar Blue reduction.
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every 3 days and subcultured before confluence was
reached.
Cell lines were transfected using Lipofectamine 2000
(Invitrogene) according to the manufacturer’s
instructions.
Molecular cloning
The number denotation of anti-MYCN (aMN) shRNAs
describes the first position of the shRNA target recogni-
tion site in the MYCN cDNA sequence (NM_005378).
Construction of the following shRNAs was performed
by annealing a sense and an antisense oligonucleotide:
aMN-887 (ON106/ON107) and aMN-1658 (ON413/
ON414). Oligonucleotide (ON) sequences are listed in
Additional file 4. Annealed oligonucleotides were ligated
into BglII/HindIII digested pENTR-H1-wt or pENTR-
H1-2O2-US/DS vectors as previously described [16] to
generate paMN-887/H1wt, paMN-887/H1-2O2, paMN-
1658/H1wt and paMN-1658/H1-2O2. Scrambled (Scr)
shRNA expressing vectors pScr/H1wt and pScr/H1-2O2
were made in a similar way using ON110/ON111. The
vectors paMN-887/H1wt and paMN-1658/H1wt were
used in transient transfection studies.
To generate the inducible retroviral expression vec-
tors pRV-1658 and pRV-Scr, the shRNA expression
modules from paMN-1658/H1-2O2 and pScr/H1-2O2
respectively, were gated into the retroviral destination
vector L193 RRI-GreenattR1ccdBCmRattR2 (a kind
gift from Dr. David Micklem) using the Gateway LR
Clonase Enzyme Mix (Invitrogen). L193 RRI-Green-
attR1ccdBCmRattR2 is based on the L071 RRI-Green
vector [30]. The U6promoter/shRNA cloning cassette
of L071 (flanked by HindIII and SalI sites) was
replaced with an attR1-ccdB-CmR-attR2 Gateway clon-
ing cassette derived from pDONR221 (Invitrogen).
This cassette allows L193 to be used as a Gateway
Destination Vector and requires that the vector is pro-
pagated in a ccdB-resistant strain. All plasmid con-
structs were verified by DNA sequencing.
Production of retroviruses, transduction and induction of
shRNA expression
Retroviral destination vectors pRV-1658 and pRV-Scr
were transfected into the Hek293-Phoenix packaging
cell line seeded in 6-well plates. 24 h after transfection,
t h ec u l t u r em e d i aw e r er e p l a c e db yf r e s hm e d i ac o r r e -
sponding to the cell line being transduced. After another
24 h of incubation, the media were passed through a
Millex HV 0.45 μm PVDF filter (Millipore, Bedford,
MA, USA) to isolate retroviral particles. Polybrene
(Sigma, St. Louis, MO, USA) was added to a final con-
centration of 4 μg/ml.
Cells were transduced by replacing the growth media
with the solution of isolated retroviruses containing
polybrene. The following day the virus-containing media
were replaced with normal growth media containing
puromycin (HEK293T-Rex and Kelly: 200 ng/ml, SK-N-
BE(2): 2500 ng/ml).
Induction of shRNA expression was performed by the
addition of 1 μg/ml doxycyclin (dox) to the media.
Quantitative real-time RT-PCR
Total RNA was extracted using the Qiagen miRNeasy
Mini Kit (Qiagen, Hilden, Germany). 1 μgt o t a lR N A
was reverse transcribed in 20 μl using a Qiagen miS-
cript Reverse Transcription Kit according to the manu-
facturer’s instructions. Real-time PCR analysis was
performed in 25 μl reactions using Power SYBR Green
PCR Master Mix (Applied Biosystems, Warrington,
UK) as recommended by the manufacturer (2.5 μlo fa
20×-diluted RT-reaction as template, 0.2 μM of each
Figure 7 Reproductive cell survival in MNA neuroblastoma
cells after MYCN knockdown. (A): Graphic presentation of colony
forming units (CFU) after induced expression (+ dox) of scrambled
(Scr) and anti-MYCN (aMN1658) shRNA in Kelly and SK-N-BE(2) cells.
(B): Representative pictures of CFU from retrovirally transduced Kelly
cells as presented in A.
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ON175) were used as reference genes for normalizing
expression levels of MYCN (ON440/ON441 and
ON145/146 were used for comparing the effect of
aMN-887 and aMN-1658), NFL (ON58/ON59), GAP43
(ON298/ON299), c-myc (ON100/ON101), TH (ON453/
ON454), ChAT (ON516/ON517), VAChT (ON518/
ON519) and NPY (ON060/ON061). Primer sequences
are listed in Additional file 4.
Quantification of the aMN-1658 shRNA was per-
formed using miScript SYBR green PCR Kit (Qiagen)
in 50 μl reactions with 1 μlo ft h e2 0 × - d i l u t e dR T -
reaction as template. Specific primers for quantifying
aMN-1658 shRNA were ordered as a custom miS-
cript Primer Assay from Qiagen using 5’CACA-
CAAGGUGACUUCAACAGUU3’ as the mature
miRNA sequence, and were used at concentrations
specified by the manufacturer. UBC and PPIA were
used for normalizing. All quantitative PCR reactions
were performed using the Applied Biosystems 7300
Real-Time PCR System (Applied Biosystems) with
thermal profiles as recommended by the manufac-
turer. The fold change in mRNA and miRNA levels
were calculated using the ΔΔCT method with the
qBASE software [31].
Western blotting
Cells were trypsinized and lysed in a Tropix Lysis Solu-
tion (Bedford, MA, USA). Lysate cleared by centrifuga-
tion was measured for total protein using Bio-Rad DC
protein assay (Bio-Rad, Hercules, CA, USA), and 35 μg
protein were loaded in each well on pre-casted NuPAGE
4-12% Bis-Tris Gels (Invitrogen). The separated proteins
were transferred to an Immobilon-FL PVDF transfer
membrane (Millipore) and blocked for 1 hour at room
temperature in Odyssey Blocking Buffer (LI-COR,
Lincoln, NE, USA) before incubation at 4°C overnight
with the following primary antibodies: mouse anti-
NMYC (Calbiochem/Merck, Darmstadt, Germany),
mouse anti-GAP43 (Abcam, Cambridge, UK), goat
anti-NFL (Santa Cruz Biotech., Santa Cruz, CA, USA)
and rabbit anti-bActin (Sigma) diluted in the blocking
buffer. Secondary antibodies were goat anti-rabbit
IRDye800CW (Rockland, Gilbertsville, PA, USA) and
goat anti-mouse Alexa Fluor 680 (Invitrogen). Antibody
binding was detected using the Odyssey Infrared Ima-
ging System (LI-COR). NFL was detected by HRP con-
jugated rabbit anti-goat secondary antibody (DAKO,
Glostrup, Denmark) and SuperSignal West Pico Chemi-
luminescent Substrate (Pierce, Rockford, IL, USA).
Luciferase assay
Retrovirus-transduced HEK293T-Rex cells were seeded
in 12-well plates. 48 hrs following induction with 1 μg/
ml dox, each well was transfected with 0.02 μg pGL4.75
[hRluc/CMV] Vector (Promega, Madison, WI, USA) and
0.1 μg pGL3 Control Vector (Promega). Firefly and
renilla luciferace activity were measured after 48 hrs
using the Dual-Luciferase Reporter Assay System (Pro-
mega) according to the manufacturer’s instructions.
Luminescence was measured on a Luminoskan Ascent
luminometer (Thermo Sci., Waltham, MA, USA).
Renilla luciferase was used to normalize the data, and all
experiments were performed in triplicate.
Clonogenic assay
The cells were grown for 7-11 days with replacement of
the media every third day. On the last day of the experi-
ment, the cells were washed once in 1 × PBS and
stained with the clonogenic reagent (50% EtOH, 0.25%
1,9-dimethyl-methylene blue) for 45 min. Cells were
washed twice in PBS before visible colonies were
counted.
Cell viability assay
The cytotoxic effect of induced MYCN knockdown on
MNA neuroblastoma cells was analysed using the Ala-
mar Blue Assay according to the manufacturer’s instruc-
tions. In brief, the cells were seeded at a density of
40000 (Kelly) and 15000 (SK-N-BE(2)) cells per well in
12-well plates. Media were replaced every second day.
On the indicated days, 100 μl of Alamar Blue solution
were added to each well and incubated for 4 hrs at
37°C. Absorbance at 570 and 600 nm was measured on
a plate reader and the relative reduction of Alamar Blue
was calculated as described by the manufacturer. The
calculated average relative reduction from three inde-
pendent experiments was calculated.
Flow cytometric analysis of cell cycle distribution
Cells were harvested using Trypsin-EDTA (Sigma-
Aldrich) and washed once in 1 × PBS. The cells were
then fixed for 2 hrs in ice-cold 70% EtOH. After fixa-
tion, the EtOH was removed by centrifugation and the
cells were washed once in 1 × PBS before being stained
for 30 min at room temperature in a propidium iodide
(PI)-staining solution (PBS with 20 μg/ml PI (Sigma),
60 μg/ml RNase A (Sigma) and 0.1% v/v Triton X-100
(Sigma)). Fluorescence emitted from the PI-DNA com-
plex was analysed by flow cytometry, using a FACS Aria
Flow Cytometer (BD Biosciences, San Jose, CA, USA).
Henriksen et al. BMC Developmental Biology 2011, 11:1
http://www.biomedcentral.com/1471-213X/11/1
Page 9 of 11Additional material
Additional file 1: Specific MYCN 3’UTR knockdown mediated by the
aMN-1658 shRNA. (A): The 3’UTR of MYCN was PCR-amplified from
human genomic DNA with primers ON178
(5’AAAGCTGCGCACTAGTATCTGGACCAGGCTGTGGGTAGA3’ -SpeI site) and
ON181 (5’ GATCAAGCTTAATTTTAAGCTATTTATTTT 3’ -HindIII site). PCR
products were digested with SpeI/HindIII and ligated into SpeI/HindIII-
digested pMIR-REPORT vector (Invitrogen) to produce Luc-MYCN-3’UTR. A
control Luc no-target (NT)-3’UTR plasmid was made by amplification of
the 3’UTR region from REIC using ON361
(5’GATCAAGCTTAATTTTAAGCTATTTATTTT3’-SpeI site) and ON327
(5’GATCAAGCTTCTATGGAAGATTTTTAATACAGG3’ -HindIII) as primers and
ligated into SpeI/HindIII digested pMIR-REPORT vector using the In-
Fusion Dry-Down PCR Cloning Kit (Clontech). HEK-293 cells were seeded
in 12-well plates, incubated for 48 hrs and transfected with a cocktail
containing: 0.02 μg pGL4.75[hRluc/CMV] Vector (Promega), 0.1 μg pMIR-
Report containing either the MYCN 3’UTR (Luc MYCN-3’UTR) or control
(Luc-NT-3’UTR), and 1 μg shRNA expressing plasmid (pScr/H1wt, paMN-
887/H1wt or paMN-1658/H1wt). Transfected cells were then incubated
for 48 hrs before luciferase activities were measured as described.(B):
Western blot analysis of MYCN and b-actin expression in SK-N-BE(2)
transfected cells. CMV-MYCN (kind gift from Dr. Jason Shohet) expresses
the MYCN cDNA lacking a 3’UTR. SK-N-BE(2) cells were transiently co-
transfected with the shRNA-expressing plasmids (pScr/H1wt, paMN-887/
H1wt or paMN-1658/H1wt) and pCMV-MYCN (+) or the shRNA-
expressing plasmids and pCMV-GFP (-). The aMN-1658 shRNA is not able
to suppress expression of MYCN from the 3’UTR-lacking pCMV-MYCN
plasmid. M = Magic Mark XP (Invitrogen).
Additional file 2: mRNA expression of neuronal markers in
neuroblastoma cell lines after transduction with inducible anti-
MYCN shRNA expressing retroviruses. Real-time RT-PCR analysis of NFL
(A) and GAP43 (B) mRNA expression in Kelly and SK-N-BE(2) cells
transduced with the retrovirus RV-1658. Cells were incubated for the
indicated numbers of days in the presence (+) or absence (-) of 1 μg/ml
doxycyclin (dox). 3/3 and +/- indicate that the cells were incubated for 3
days in the presence of dox, followed by 3 days in the absence of dox.
(C): Real-time RT-PCR analysis of ChAT, VAChT, TH and NPY mRNA in RV-
1658 transduced Kelly and SK-N-BE(2) cells grown in the absence (-) or
presence (+) of doxycyclin (dox) for 6 days.
Additional file 3: Cell cycle distribution of neuroblastoma cell lines
after transduction with inducible anti-MYCN shRNA expressing
retroviruses. Flow cytometric analysis showing the cell cycle distribution
of Kelly (A) and SK-N-BE(2) (B) cells transduced with the RV-1658 and RV-
Scr retroviruses in the presence (+) or absence (-) of 1 μg/ml doxycyclin
(dox).
Additional file 4: Oligonucleotides. Oligonucleotides used in this study.
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